New technologies and therapies in the management of diabetes.

Publisher: Clinical Care Targeted Communications Group, LLC Country of Publication: United States NLM ID: 9613960 Publication Model: Print Cited Medium: Internet ISSN: 1936-2692 (Electronic) Linking ISSN: 10880224 NLM ISO Abbreviation: Am J Manag Care

Publication: Cranbury, NJ : Clinical Care Targeted Communications Group, LLC
Original Publication: Old Bridge, NJ : American Medical Pub., c1995-

Diabetes Mellitus, Type 1/*drug therapy ; Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/*therapeutic use ; Insulin/*therapeutic use; Administration, Inhalation ; Blood Glucose/analysis ; Diabetes Mellitus, Type 1/diagnosis ; Diabetes Mellitus, Type 1/mortality ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/mortality ; Disease Management ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Male ; Managed Care Programs ; Prognosis ; Randomized Controlled Trials as Topic ; Risk Assessment ; Sickness Impact Profile ; Survival Analysis ; Treatment Outcome ; United States ; United States Food and Drug Administration

Although there are numerous effective pharmacotherapeutic agents available to treat type 2 diabetes, 5% to 10% of the population with diabetes experience secondary failure. To help combat this issue, it is imperative that clinicians understand the limitations of some current therapies. Secondary failure can be due to decreasing beta cell function, poor adherence to treatment, weight gain, reduction of exercise, changes in diet, or illness. Glycemic control and cardiovascular risk reduction are of paramount concern; however, the nonglycemic effects of several new therapies to treat diabetes may be advantageous and positively affect the long-term cost of therapy. The discoveries of amylin and glucagonlike peptide-1 have furthered our understanding of the abnormalities involved in diabetes, enabling the development of additional therapeutic options. Incretin-based therapy, including incretin mimetics such as exenatide and the yet-to-be-approved dipeptidyl peptidase-4 inhibitors, and new basal and inhaled insulin may change the way we currently treat type 2 diabetes.

48

0 (Blood Glucose)
0 (Exubera)
0 (Hypoglycemic Agents)
0 (Insulin)

Date Created: 20070410 Date Completed: 20070502 Latest Revision: 20111117

20231215

17417933